Proposition - PharmXpert Academy

More documents

Recommendations

Info

The Korean Pharmaceutical Company List 491 55. SAMJIN PHARM 1. Company Information Company SAMJIN PHARM Representative Sung-Woo, Lee E-mail webmaster@samjinpharm.co.kr Representative Phone No. 82-2-338-5511 Representative Fax No. 82-2-392-5312 Homepage Address Research Institute Address Year of Establishment http://www.samjinpharm.co.kr/ 338-8 Seokyo-dong, Mapo-gu, Seoul, Rep. of KOREA Factory: 904-2 Sangshin-ri, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Rep. of KOREA 1970 Sales (‘06) 128.5 Million$ The Number of Employees (06‘) Total The Number of 503 Researchers (‘06) 21 Total Contact Person Lee, Sung il Contact Phone 82-2-3140-0679 Contact E-mail drrun2u@hotmail.com Contact Fax 82-2-392-5315 Introduction of Company All human beings have rights to live happy and healthy lives. However, a modern society has brought complicated structures and developed material civilization, which has caused many new diseases. In order to protect human health from the diseases and to eliminate the causes, Samjin Pharmaceuticals challenge for the continuous development of excellent medical products by securing superior intelligence, latest tools and materials, and advanced scientific information and technology. Samjin Pharmaceuticals always make the best effort toward future with regarding the dignity of a human life as the basis of the corporate spirit. "The corporate which develops healthy human lives and challenges for fruitful future with the spirit of creativity - that is Samjin Pharmaceuticals."
492 2007 Korea Pharmaceutical Industry Directory 2. Main Products Information No. Name of Products Main Ingredient Use (Indications) Formulation Date of Sales Expected Exporting Countries Etc. 1 JEMTRA INJ. Gemcitabine HCl 228mg For non-small cell pulmonary cancer Inj. 2 URETOL SR TAB. L-Tolterodine Tartrate 4mg For urgent, frequent urine or urgent incontinent urine Tab. 3 PLATLESS TAB. Clopidogrel bisulfate(USP) For stroke, myocardiac infarction and peripheral artery disease Tab. 4 GEL2 Suspension Almagate(KPC) For stomach and duodenal ulcers Sol. 5 CERAZINE-S CAP. Cetirizine HCl (B.P) For snuffle, sneeze, rhinorrhea, and itching eye or nose Cap. 6 AIDBONE TAB. Alendronic acid 70mg Treatment for osteoporosis Cab. 7 LADYFERRIN-F CAP. Prevention and treatment for iron-deficiency anemia, ulcerative colitis and stomach and duodenal ulcers Cap. 8 WELLTAMIN SOFT CAP. Relief of peripheral circulation disturbance and those symptoms when menopause such as stiff neck or shoulder, tingling limbs abd cold limbs Cap. 9 ACEPECT CAP. For acute, chronic respiratory diseases Cap. 10 TAMSPEED CAP. Tamsulosin HCl 0.2mg For dysuria by benign prostatism Cap. 3. R&D Figures Research Task Research Term R & D and Expectancy 1. Developing Treatment for AIDS Processing To produce new medicine 2. Developing anticancer agent 〃〃 Others Improving the process after technological transfers Improving the process after technological transfers 3. Developing treatment for diabetes 〃〃 Performing own research 4. Developing treatment for impotence 〃〃 Performing own research 5. Developing treatment for dementia 〃〃 Performing own research 6. Developing differentiation-inducing method of pancreas β-cell from human embryonic stem cell 7. Developing treatment for Type-C hepatitis 〃〃 8. Developing inhibitor against coronavirus 〃〃〃〃 National task Performing own research (Patent application) Performing own research (Patent applicaiton) 9. Developing inhibitor against influenza 〃〃 Performing own research
Page 2 and 3:
2007 Korea Pharmaceutical Industry
Page 4 and 5:
2007 Korea Pharmaceutical Industry
Page 6 and 7:
27. ILYANG PHARM ·········
Page 8 and 9:
Chapter 1. Outline of The Project 2
Page 10 and 11:
Chapter 1. Outline of The Project 2
Page 12 and 13:
Chapter 2. Pharmaceutical Industry
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
The Annex
Page 38 and 39:
316 2007 Korea Pharmaceutical Indus
Page 40 and 41:
The Korean Pharmaceutical Company L
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
4. Company Map The Korean Pharmace
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163: The Korean Pharmaceutical Company L
Page 200 and 201: 4. Company Map The Korean Pharmace
Page 254 and 255: 3. Company Map The Korean Pharmace
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
show all

Proposition - PharmXpert Academy

Create successful ePaper yourself

Delete template?

Save as template?